Get Real Time Here
| Open2.715 | Close2.560 |
| Vol / Avg.36.104K / 126.991K | Mkt Cap123.372M |
| Day Range2.505 - 2.805 | 52 Wk Range1.470 - 6.030 |
TScan Therapeutics Stock (NASDAQ:TCRX), Quotes and News Summary
TScan Therapeutics Stock (NASDAQ: TCRX) stock price, news, charts, stock research, profile.
| Open2.715 | Close2.560 |
| Vol / Avg.36.104K / 126.991K | Mkt Cap123.372M |
| Day Range2.505 - 2.805 | 52 Wk Range1.470 - 6.030 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.780 | -0.510 | 0.2700 | ||||
| REV | 4.030M | 3.148M | -882.000K |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-14 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-06-22 | Wedbush | David Nierengarten | Initiates Coverage On | Outperform | Announces | - | 8.00 |
| 2023-05-18 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-05-11 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| TCRX | TScan Therapeutics | -1.53% | 123.4M |
| MOLN | Molecular Partners | -0.72% | 135.9M |
| GRPH | Graphite Bio | 4.64% | 143.8M |
| GALT | Galectin Therapeutics | 1.05% | 114.4M |
| ALT | Altimmune | 4% | 137M |
How do I buy TScan Therapeutics (TCRX) stock?
You can purchase shares of TScan Therapeutics (NASDAQ: TCRX) through any online brokerage.
Who are TScan Therapeutics's (TCRX) competitors?
Other companies in TScan Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Graphite Bio (NASDAQ:GRPH), Galectin Therapeutics (NASDAQ:GALT), Altimmune (NASDAQ:ALT) and PepGen (NASDAQ:PEPG).
What is the target price for TScan Therapeutics (TCRX) stock?
The latest price target for TScan Therapeutics (NASDAQ: TCRX) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 15.00 expecting TCRX to rise to within 12 months (a possible 481.40% upside). 5 analyst firms have reported ratings in the last year.
Current Stock Price for TScan Therapeutics (TCRX)?
The stock price for TScan Therapeutics (NASDAQ: TCRX) is $2.58 last updated September 22, 2023 at 11:52 AM UTC.
Does TScan Therapeutics (TCRX) pay a dividend?
A quarterly cash dividend of $0.42 per share of Class A Common Stock. The quarterly cash dividend was payable on June 30, 2018 to stockholders of record on June 14, 2018.
When is TScan Therapeutics (NASDAQ:TCRX) reporting earnings?
TScan Therapeutics’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
Is TScan Therapeutics (TCRX) going to split?
There is no upcoming split for TScan Therapeutics.
What sector and industry does TScan Therapeutics (TCRX) operate in?
TScan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
TScan Therapeutics Stock (NASDAQ:TCRX), Quotes and News Summary
TScan Therapeutics Stock (NASDAQ: TCRX) stock price, news, charts, stock research, profile.
| Open2.715 | Close2.560 |
| Vol / Avg.36.104K / 126.991K | Mkt Cap123.372M |
| Day Range2.505 - 2.805 | 52 Wk Range1.470 - 6.030 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.780 | -0.510 | 0.2700 | ||||
| REV | 4.030M | 3.148M | -882.000K |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-14 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-06-22 | Wedbush | David Nierengarten | Initiates Coverage On | Outperform | Announces | - | 8.00 |
| 2023-05-18 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-05-11 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| TCRX | TScan Therapeutics | -1.53% | 123.4M |
| MOLN | Molecular Partners | -0.72% | 135.9M |
| GRPH | Graphite Bio | 4.64% | 143.8M |
| GALT | Galectin Therapeutics | 1.05% | 114.4M |
| ALT | Altimmune | 4% | 137M |
How do I buy TScan Therapeutics (TCRX) stock?
You can purchase shares of TScan Therapeutics (NASDAQ: TCRX) through any online brokerage.
Who are TScan Therapeutics's (TCRX) competitors?
Other companies in TScan Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Graphite Bio (NASDAQ:GRPH), Galectin Therapeutics (NASDAQ:GALT), Altimmune (NASDAQ:ALT) and PepGen (NASDAQ:PEPG).
What is the target price for TScan Therapeutics (TCRX) stock?
The latest price target for TScan Therapeutics (NASDAQ: TCRX) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 15.00 expecting TCRX to rise to within 12 months (a possible 481.40% upside). 5 analyst firms have reported ratings in the last year.
Current Stock Price for TScan Therapeutics (TCRX)?
The stock price for TScan Therapeutics (NASDAQ: TCRX) is $2.58 last updated September 22, 2023 at 11:52 AM UTC.
Does TScan Therapeutics (TCRX) pay a dividend?
A quarterly cash dividend of $0.42 per share of Class A Common Stock. The quarterly cash dividend was payable on June 30, 2018 to stockholders of record on June 14, 2018.
When is TScan Therapeutics (NASDAQ:TCRX) reporting earnings?
TScan Therapeutics’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
Is TScan Therapeutics (TCRX) going to split?
There is no upcoming split for TScan Therapeutics.
What sector and industry does TScan Therapeutics (TCRX) operate in?
TScan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
TScan Therapeutics Stock (NASDAQ:TCRX), Quotes and News Summary
TScan Therapeutics Stock (NASDAQ: TCRX) stock price, news, charts, stock research, profile.
| Open2.715 | Close2.560 |
| Vol / Avg.36.104K / 126.991K | Mkt Cap123.372M |
| Day Range2.505 - 2.805 | 52 Wk Range1.470 - 6.030 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.780 | -0.510 | 0.2700 | ||||
| REV | 4.030M | 3.148M | -882.000K |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-14 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-06-22 | Wedbush | David Nierengarten | Initiates Coverage On | Outperform | Announces | - | 8.00 |
| 2023-05-18 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-05-11 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| TCRX | TScan Therapeutics | -1.53% | 123.4M |
| MOLN | Molecular Partners | -0.72% | 135.9M |
| GRPH | Graphite Bio | 4.64% | 143.8M |
| GALT | Galectin Therapeutics | 1.05% | 114.4M |
| ALT | Altimmune | 4% | 137M |
How do I buy TScan Therapeutics (TCRX) stock?
You can purchase shares of TScan Therapeutics (NASDAQ: TCRX) through any online brokerage.
Who are TScan Therapeutics's (TCRX) competitors?
Other companies in TScan Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Graphite Bio (NASDAQ:GRPH), Galectin Therapeutics (NASDAQ:GALT), Altimmune (NASDAQ:ALT) and PepGen (NASDAQ:PEPG).
What is the target price for TScan Therapeutics (TCRX) stock?
The latest price target for TScan Therapeutics (NASDAQ: TCRX) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 15.00 expecting TCRX to rise to within 12 months (a possible 481.40% upside). 5 analyst firms have reported ratings in the last year.
Current Stock Price for TScan Therapeutics (TCRX)?
The stock price for TScan Therapeutics (NASDAQ: TCRX) is $2.58 last updated September 22, 2023 at 11:52 AM UTC.
Does TScan Therapeutics (TCRX) pay a dividend?
A quarterly cash dividend of $0.42 per share of Class A Common Stock. The quarterly cash dividend was payable on June 30, 2018 to stockholders of record on June 14, 2018.
When is TScan Therapeutics (NASDAQ:TCRX) reporting earnings?
TScan Therapeutics’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
Is TScan Therapeutics (TCRX) going to split?
There is no upcoming split for TScan Therapeutics.
What sector and industry does TScan Therapeutics (TCRX) operate in?
TScan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
TScan Therapeutics Stock (NASDAQ:TCRX), Quotes and News Summary
TScan Therapeutics Stock (NASDAQ: TCRX) stock price, news, charts, stock research, profile.
| Open2.715 | Close2.560 |
| Vol / Avg.36.104K / 126.991K | Mkt Cap123.372M |
| Day Range2.505 - 2.805 | 52 Wk Range1.470 - 6.030 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.780 | -0.510 | 0.2700 | ||||
| REV | 4.030M | 3.148M | -882.000K |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-14 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-06-22 | Wedbush | David Nierengarten | Initiates Coverage On | Outperform | Announces | - | 8.00 |
| 2023-05-18 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-05-11 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| TCRX | TScan Therapeutics | -1.53% | 123.4M |
| MOLN | Molecular Partners | -0.72% | 135.9M |
| GRPH | Graphite Bio | 4.64% | 143.8M |
| GALT | Galectin Therapeutics | 1.05% | 114.4M |
| ALT | Altimmune | 4% | 137M |
How do I buy TScan Therapeutics (TCRX) stock?
You can purchase shares of TScan Therapeutics (NASDAQ: TCRX) through any online brokerage.
Who are TScan Therapeutics's (TCRX) competitors?
Other companies in TScan Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Graphite Bio (NASDAQ:GRPH), Galectin Therapeutics (NASDAQ:GALT), Altimmune (NASDAQ:ALT) and PepGen (NASDAQ:PEPG).
What is the target price for TScan Therapeutics (TCRX) stock?
The latest price target for TScan Therapeutics (NASDAQ: TCRX) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 15.00 expecting TCRX to rise to within 12 months (a possible 481.40% upside). 5 analyst firms have reported ratings in the last year.
Current Stock Price for TScan Therapeutics (TCRX)?
The stock price for TScan Therapeutics (NASDAQ: TCRX) is $2.58 last updated September 22, 2023 at 11:52 AM UTC.
Does TScan Therapeutics (TCRX) pay a dividend?
A quarterly cash dividend of $0.42 per share of Class A Common Stock. The quarterly cash dividend was payable on June 30, 2018 to stockholders of record on June 14, 2018.
When is TScan Therapeutics (NASDAQ:TCRX) reporting earnings?
TScan Therapeutics’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
Is TScan Therapeutics (TCRX) going to split?
There is no upcoming split for TScan Therapeutics.
What sector and industry does TScan Therapeutics (TCRX) operate in?
TScan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
TScan Therapeutics Stock (NASDAQ:TCRX), Quotes and News Summary
TScan Therapeutics Stock (NASDAQ: TCRX) stock price, news, charts, stock research, profile.
| Open2.715 | Close2.560 |
| Vol / Avg.36.104K / 126.991K | Mkt Cap123.372M |
| Day Range2.505 - 2.805 | 52 Wk Range1.470 - 6.030 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.780 | -0.510 | 0.2700 | ||||
| REV | 4.030M | 3.148M | -882.000K |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-14 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-06-22 | Wedbush | David Nierengarten | Initiates Coverage On | Outperform | Announces | - | 8.00 |
| 2023-05-18 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-05-11 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| TCRX | TScan Therapeutics | -1.53% | 123.4M |
| MOLN | Molecular Partners | -0.72% | 135.9M |
| GRPH | Graphite Bio | 4.64% | 143.8M |
| GALT | Galectin Therapeutics | 1.05% | 114.4M |
| ALT | Altimmune | 4% | 137M |
How do I buy TScan Therapeutics (TCRX) stock?
You can purchase shares of TScan Therapeutics (NASDAQ: TCRX) through any online brokerage.
Who are TScan Therapeutics's (TCRX) competitors?
Other companies in TScan Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Graphite Bio (NASDAQ:GRPH), Galectin Therapeutics (NASDAQ:GALT), Altimmune (NASDAQ:ALT) and PepGen (NASDAQ:PEPG).
What is the target price for TScan Therapeutics (TCRX) stock?
The latest price target for TScan Therapeutics (NASDAQ: TCRX) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 15.00 expecting TCRX to rise to within 12 months (a possible 481.40% upside). 5 analyst firms have reported ratings in the last year.
Current Stock Price for TScan Therapeutics (TCRX)?
The stock price for TScan Therapeutics (NASDAQ: TCRX) is $2.58 last updated September 22, 2023 at 11:52 AM UTC.
Does TScan Therapeutics (TCRX) pay a dividend?
A quarterly cash dividend of $0.42 per share of Class A Common Stock. The quarterly cash dividend was payable on June 30, 2018 to stockholders of record on June 14, 2018.
When is TScan Therapeutics (NASDAQ:TCRX) reporting earnings?
TScan Therapeutics’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
Is TScan Therapeutics (TCRX) going to split?
There is no upcoming split for TScan Therapeutics.
What sector and industry does TScan Therapeutics (TCRX) operate in?
TScan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
TScan Therapeutics Stock (NASDAQ:TCRX), Quotes and News Summary
TScan Therapeutics Stock (NASDAQ: TCRX) stock price, news, charts, stock research, profile.
| Open2.715 | Close2.560 |
| Vol / Avg.36.104K / 126.991K | Mkt Cap123.372M |
| Day Range2.505 - 2.805 | 52 Wk Range1.470 - 6.030 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.780 | -0.510 | 0.2700 | ||||
| REV | 4.030M | 3.148M | -882.000K |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-14 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-06-22 | Wedbush | David Nierengarten | Initiates Coverage On | Outperform | Announces | - | 8.00 |
| 2023-05-18 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-05-11 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| TCRX | TScan Therapeutics | -1.53% | 123.4M |
| MOLN | Molecular Partners | -0.72% | 135.9M |
| GRPH | Graphite Bio | 4.64% | 143.8M |
| GALT | Galectin Therapeutics | 1.05% | 114.4M |
| ALT | Altimmune | 4% | 137M |
How do I buy TScan Therapeutics (TCRX) stock?
You can purchase shares of TScan Therapeutics (NASDAQ: TCRX) through any online brokerage.
Who are TScan Therapeutics's (TCRX) competitors?
Other companies in TScan Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Graphite Bio (NASDAQ:GRPH), Galectin Therapeutics (NASDAQ:GALT), Altimmune (NASDAQ:ALT) and PepGen (NASDAQ:PEPG).
What is the target price for TScan Therapeutics (TCRX) stock?
The latest price target for TScan Therapeutics (NASDAQ: TCRX) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 15.00 expecting TCRX to rise to within 12 months (a possible 481.40% upside). 5 analyst firms have reported ratings in the last year.
Current Stock Price for TScan Therapeutics (TCRX)?
The stock price for TScan Therapeutics (NASDAQ: TCRX) is $2.58 last updated September 22, 2023 at 11:52 AM UTC.
Does TScan Therapeutics (TCRX) pay a dividend?
A quarterly cash dividend of $0.42 per share of Class A Common Stock. The quarterly cash dividend was payable on June 30, 2018 to stockholders of record on June 14, 2018.
When is TScan Therapeutics (NASDAQ:TCRX) reporting earnings?
TScan Therapeutics’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
Is TScan Therapeutics (TCRX) going to split?
There is no upcoming split for TScan Therapeutics.
What sector and industry does TScan Therapeutics (TCRX) operate in?
TScan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
TScan Therapeutics Stock (NASDAQ:TCRX), Quotes and News Summary
TScan Therapeutics Stock (NASDAQ: TCRX) stock price, news, charts, stock research, profile.
| Open2.715 | Close2.560 |
| Vol / Avg.36.104K / 126.991K | Mkt Cap123.372M |
| Day Range2.505 - 2.805 | 52 Wk Range1.470 - 6.030 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.780 | -0.510 | 0.2700 | ||||
| REV | 4.030M | 3.148M | -882.000K |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-14 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-06-22 | Wedbush | David Nierengarten | Initiates Coverage On | Outperform | Announces | - | 8.00 |
| 2023-05-18 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-05-11 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| TCRX | TScan Therapeutics | -1.53% | 123.4M |
| MOLN | Molecular Partners | -0.72% | 135.9M |
| GRPH | Graphite Bio | 4.64% | 143.8M |
| GALT | Galectin Therapeutics | 1.05% | 114.4M |
| ALT | Altimmune | 4% | 137M |
How do I buy TScan Therapeutics (TCRX) stock?
You can purchase shares of TScan Therapeutics (NASDAQ: TCRX) through any online brokerage.
Who are TScan Therapeutics's (TCRX) competitors?
Other companies in TScan Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Graphite Bio (NASDAQ:GRPH), Galectin Therapeutics (NASDAQ:GALT), Altimmune (NASDAQ:ALT) and PepGen (NASDAQ:PEPG).
What is the target price for TScan Therapeutics (TCRX) stock?
The latest price target for TScan Therapeutics (NASDAQ: TCRX) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 15.00 expecting TCRX to rise to within 12 months (a possible 481.40% upside). 5 analyst firms have reported ratings in the last year.
Current Stock Price for TScan Therapeutics (TCRX)?
The stock price for TScan Therapeutics (NASDAQ: TCRX) is $2.58 last updated September 22, 2023 at 11:52 AM UTC.
Does TScan Therapeutics (TCRX) pay a dividend?
A quarterly cash dividend of $0.42 per share of Class A Common Stock. The quarterly cash dividend was payable on June 30, 2018 to stockholders of record on June 14, 2018.
When is TScan Therapeutics (NASDAQ:TCRX) reporting earnings?
TScan Therapeutics’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
Is TScan Therapeutics (TCRX) going to split?
There is no upcoming split for TScan Therapeutics.
What sector and industry does TScan Therapeutics (TCRX) operate in?
TScan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
TScan Therapeutics Stock (NASDAQ:TCRX), Quotes and News Summary
TScan Therapeutics Stock (NASDAQ: TCRX) stock price, news, charts, stock research, profile.
| Open2.715 | Close2.560 |
| Vol / Avg.36.104K / 126.991K | Mkt Cap123.372M |
| Day Range2.505 - 2.805 | 52 Wk Range1.470 - 6.030 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.780 | -0.510 | 0.2700 | ||||
| REV | 4.030M | 3.148M | -882.000K |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-14 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-06-22 | Wedbush | David Nierengarten | Initiates Coverage On | Outperform | Announces | - | 8.00 |
| 2023-05-18 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-05-11 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| TCRX | TScan Therapeutics | -1.53% | 123.4M |
| MOLN | Molecular Partners | -0.72% | 135.9M |
| GRPH | Graphite Bio | 4.64% | 143.8M |
| GALT | Galectin Therapeutics | 1.05% | 114.4M |
| ALT | Altimmune | 4% | 137M |
How do I buy TScan Therapeutics (TCRX) stock?
You can purchase shares of TScan Therapeutics (NASDAQ: TCRX) through any online brokerage.
Who are TScan Therapeutics's (TCRX) competitors?
Other companies in TScan Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Graphite Bio (NASDAQ:GRPH), Galectin Therapeutics (NASDAQ:GALT), Altimmune (NASDAQ:ALT) and PepGen (NASDAQ:PEPG).
What is the target price for TScan Therapeutics (TCRX) stock?
The latest price target for TScan Therapeutics (NASDAQ: TCRX) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 15.00 expecting TCRX to rise to within 12 months (a possible 481.40% upside). 5 analyst firms have reported ratings in the last year.
Current Stock Price for TScan Therapeutics (TCRX)?
The stock price for TScan Therapeutics (NASDAQ: TCRX) is $2.58 last updated September 22, 2023 at 11:52 AM UTC.
Does TScan Therapeutics (TCRX) pay a dividend?
A quarterly cash dividend of $0.42 per share of Class A Common Stock. The quarterly cash dividend was payable on June 30, 2018 to stockholders of record on June 14, 2018.
When is TScan Therapeutics (NASDAQ:TCRX) reporting earnings?
TScan Therapeutics’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
Is TScan Therapeutics (TCRX) going to split?
There is no upcoming split for TScan Therapeutics.
What sector and industry does TScan Therapeutics (TCRX) operate in?
TScan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
TScan Therapeutics Stock (NASDAQ:TCRX), Quotes and News Summary
TScan Therapeutics Stock (NASDAQ: TCRX) stock price, news, charts, stock research, profile.
| Open2.715 | Close2.560 |
| Vol / Avg.36.104K / 126.991K | Mkt Cap123.372M |
| Day Range2.505 - 2.805 | 52 Wk Range1.470 - 6.030 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED) | ||||||
| REV | |||||||
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.780 | -0.510 | 0.2700 | ||||
| REV | 4.030M | 3.148M | -882.000K |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-08-14 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-06-22 | Wedbush | David Nierengarten | Initiates Coverage On | Outperform | Announces | - | 8.00 |
| 2023-05-18 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
| 2023-05-11 | HC Wainwright & Co. | Andrew Fein | Reiterates | BuyBuy | Maintains | - | 15.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| TCRX | TScan Therapeutics | -1.53% | 123.4M |
| MOLN | Molecular Partners | -0.72% | 135.9M |
| GRPH | Graphite Bio | 4.64% | 143.8M |
| GALT | Galectin Therapeutics | 1.05% | 114.4M |
| ALT | Altimmune | 4% | 137M |
How do I buy TScan Therapeutics (TCRX) stock?
You can purchase shares of TScan Therapeutics (NASDAQ: TCRX) through any online brokerage.
Who are TScan Therapeutics's (TCRX) competitors?
Other companies in TScan Therapeutics’s space includes: Molecular Partners (NASDAQ:MOLN), Graphite Bio (NASDAQ:GRPH), Galectin Therapeutics (NASDAQ:GALT), Altimmune (NASDAQ:ALT) and PepGen (NASDAQ:PEPG).
What is the target price for TScan Therapeutics (TCRX) stock?
The latest price target for TScan Therapeutics (NASDAQ: TCRX) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 15.00 expecting TCRX to rise to within 12 months (a possible 481.40% upside). 5 analyst firms have reported ratings in the last year.
Current Stock Price for TScan Therapeutics (TCRX)?
The stock price for TScan Therapeutics (NASDAQ: TCRX) is $2.58 last updated September 22, 2023 at 11:52 AM UTC.
Does TScan Therapeutics (TCRX) pay a dividend?
A quarterly cash dividend of $0.42 per share of Class A Common Stock. The quarterly cash dividend was payable on June 30, 2018 to stockholders of record on June 14, 2018.
When is TScan Therapeutics (NASDAQ:TCRX) reporting earnings?
TScan Therapeutics’s Q3 earnings are confirmed for Wednesday, November 8, 2023.
Is TScan Therapeutics (TCRX) going to split?
There is no upcoming split for TScan Therapeutics.
What sector and industry does TScan Therapeutics (TCRX) operate in?
TScan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.